Cargando…
Glutamine Antagonist GA-607 Causes a Dramatic Accumulation of FGAR which can be used to Monitor Target Engagement
BACKGROUND: Metabolomic analyses from our group and others have shown that tumors treated with glutamine antagonists (GA) exhibit robust accumulation of formylglycinamide ribonucleotide (FGAR), an intermediate in the de novo purine synthesis pathway. The increase in FGAR is attributed to the inhibit...
Autores principales: | Alt, Jesse, Gori, Sadakatali S., Lemberg, Kathryn M., Pal, Arindom, Veeravalli, Vijayabhaskar, Wu, Ying, Aguilar, Joanna M.H., Dash, Ranjeet P., Tenora, Lukáš, Majer, Pavel, Sun, Qi, Slusher, Barbara S., Rais, Rana |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Bentham Science Publishers
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8684803/ https://www.ncbi.nlm.nih.gov/pubmed/34488583 http://dx.doi.org/10.2174/1389200222666210831125041 |
Ejemplares similares
-
Discovery of tert-Butyl Ester Based
6-Diazo-5-oxo-l-norleucine Prodrugs
for Enhanced Metabolic Stability and Tumor Delivery
por: Novotná, Kateřina, et al.
Publicado: (2023) -
Clinical development of metabolic inhibitors for oncology
por: Lemberg, Kathryn M., et al.
Publicado: (2022) -
Discovery of DRP-104, a tumor-targeted metabolic inhibitor prodrug
por: Rais, Rana, et al.
Publicado: (2022) -
D-DOPA Is a Potent, Orally Bioavailable, Allosteric Inhibitor of Glutamate Carboxypeptidase II
por: Gori, Sadakatali S., et al.
Publicado: (2022) -
Pro-905, a Novel Purine Antimetabolite, Combines with Glutamine Amidotransferase Inhibition to Suppress Growth of Malignant Peripheral Nerve Sheath Tumor
por: Lemberg, Kathryn M., et al.
Publicado: (2023)